Medullary Thyroid Carcinoma Preoperative Evaluation: Ultrasound, Calcitonin, and Cytology Insights
Medullary thyroid carcinoma (MTC) is rare—accounting for just 2% to 5% of thyroid cancers—but it’s far more aggressive than other types, often spreading to lymph nodes or returning after treatment. For patients, a correct preoperative diagnosis is critical: it helps surgeons choose the right procedure and improves outcomes. But MTC can be tricky to spot on ultrasound, the most common tool for evaluating thyroid nodules. A 2019 study by researchers at China’s National Cancer Center aimed to fix this by analyzing why ultrasound sometimes misses MTC—and how combining it with other tests improves accuracy.
Study Overview
The team reviewed data from 71 patients (96 thyroid lesions) with histopathologically confirmed MTC treated between 2011 and 2016. All patients had preoperative ultrasound; some also had serum calcitonin (a hormone linked to MTC) or fine needle aspiration (FNA, a biopsy using a thin needle).
Patients were split into two groups:
- Ultrasonic Correct Diagnosis Group: Ultrasound suggested cancer or a malignant tendency.
- Ultrasonic Misdiagnosed Group: Ultrasound called the nodule benign or recommended “close follow-up.”
The goal? Compare clinical and ultrasound features between the two groups to find patterns in misdiagnosis.
Key Findings: Why Ultrasound Sometimes Misses MTC
Ultrasound is great at spotting classic thyroid cancer signs (e.g., irregular edges, tiny calcifications). But MTC can look “benign” on ultrasound—and that’s where mistakes happen. Here’s what the study found:
1. Atypical Ultrasound Features Lead to Misdiagnosis
MTC lesions in the misdiagnosed group were more likely to have:
- Cystic change: 25% vs. 4% in the correct group (cystic = fluid-filled areas, which are often benign-looking).
- Smooth edges (circumscribed margins): 79% vs. 25%.
- Regular shape: 58% vs. 13%.
- No calcification: 79% vs. 44%.
- Little to no blood flow: 42% had no vascularity vs. 6% in the correct group.
In short: If an MTC doesn’t have the “scary” ultrasound signs (irregular, calcified, blood-rich), it’s easy to mistake for a harmless nodule.
2. Serum Calcitonin Is a Game-Changer
MTC starts in parafollicular cells, which make calcitonin. The study found:
- 98.5% of patients had elevated calcitonin (only 1 case was normal, likely due to a tiny 0.3cm tumor).
- Calcitonin levels were much higher in the correct diagnosis group (median 932 ng/mL vs. 86 ng/mL in misdiagnosed).
Even when ultrasound looked benign, high calcitonin was a red flag. For example, one patient had three “benign” FNA results—but their calcitonin was sky-high. Surgery confirmed MTC.
3. FNA Works Better With Extra Tests
FNA (biopsy) is a standard preoperative tool, but it’s less accurate for MTC (67.6% accuracy) than for papillary thyroid cancer (the most common type). Why? MTC cells can look like other thyroid cells under a microscope.
The fix? Add calcitonin measurements to FNA washout fluid or immunohistochemistry (staining cells to spot MTC markers). The study found these steps drastically improve FNA’s accuracy—critical for avoiding misdiagnosis.
4. Lymph Node Metastasis Is Common (But Hard to Spot Preoperatively)
MTC spreads to neck lymph nodes in 69% of cases (per the study), but ultrasound only caught 49% of these before surgery. This means surgeons need to be extra vigilant about checking lymph nodes during operation—even if ultrasound looks clear.
What This Means for Patients and Doctors
For patients:
- If you have a thyroid nodule, ask your doctor about serum calcitonin—especially if the nodule is large, cystic, or has smooth edges.
- If FNA is recommended, ask if calcitonin washout or immunohistochemistry will be included.
For doctors:
- Don’t rely on ultrasound alone for MTC. A nodule with “benign” ultrasound features (smooth, no calcification) could still be MTC—check calcitonin.
- Use FNA with calcitonin washout to boost accuracy.
Conclusion
MTC is a tricky cancer, but this study makes one thing clear: no single test is perfect. Ultrasound is essential, but it misses atypical cases. Serum calcitonin adds a critical layer of information, and FNA works best when paired with calcitonin or immunohistochemistry. For patients and doctors, the takeaway is simple: combine tests to get the full picture.
Original Study Citation:
Guo QQ, Zhang SH, Niu LJ, Zhang YK, Li ZJ, Chang Q. Comprehensive evaluation of medullary thyroid carcinoma before surgery. Chinese Medical Journal. 2019;132(7):834–841.
DOI: doi.org/10.1097/CM9.0000000000000160
Was this helpful?
0 / 0